Compare SHEN & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHEN | ORIC |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | 1041 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.2M | 837.3M |
| IPO Year | 1994 | 2020 |
| Metric | SHEN | ORIC |
|---|---|---|
| Price | $15.97 | $8.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $26.00 | $19.73 |
| AVG Volume (30 Days) | 358.5K | ★ 1.3M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $357,854,000.00 | N/A |
| Revenue This Year | $7.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $9.67 | $4.65 |
| 52 Week High | $17.35 | $14.93 |
| Indicator | SHEN | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 31.58 |
| Support Level | $12.66 | $7.90 |
| Resistance Level | $17.13 | $13.89 |
| Average True Range (ATR) | 0.96 | 0.50 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 76.18 | 4.87 |
Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.